Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| QUCY | 8-K | mixed | 5/10 | Quantum Cyber N.V. amended its IP license agreement with BP United, eliminating a $5M cash payment to BP United and inst | Jun 3, 2026 |
| MRVI | 8-K | bullish | 6/10 | Maravai LifeSciences refinanced its prior credit agreement by entering into a new $150.0 million term loan and $30.0 mil | Jun 3, 2026 |
| CRDF | 8-K | bullish | 7/10 | Cardiff Oncology released an investor presentation detailing interim Phase 2 CRDF-004 data for onvansertib in first-line | Jun 3, 2026 |
| INAB | PRESS-RELEASE | neutral | 3/10 | IN8bio announced the publication of a review article in Nature Communications co-authored by its CSO, highlighting advan | Jun 3, 2026 |
| HOTH | 8-K | neutral | 2/10 | Rocket One Inc. appointed retired U.S. Army Major General Malcolm B. Frost to its Space and Defense Advisory Board. Gene | Jun 3, 2026 |
| HOTH | 8-K | bearish | 5/10 | Rocket One Inc. increased its at-the-market (ATM) offering capacity by up to $6.829 million in additional common stock, | Jun 3, 2026 |
| HOTH | 424B5 | bearish | 6/10 | Rocket One Inc. filed Amendment No. 2 to its prospectus supplement, increasing the aggregate amount of common stock it m | Jun 3, 2026 |
| NRXP | PRESS-RELEASE | bearish | 6/10 | NRx Pharmaceuticals priced an underwritten public offering of 5,714,286 shares at $3.50/share, with gross proceeds of ~$ | Jun 3, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber published an inaugural corporate investor presentation consolidating previously announced milestones: LOIs | Jun 3, 2026 |
| RNAZ | 8-K | bullish | 6/10 | TransCode Therapeutics announced successful completion of its Phase 1a dose escalation trial for TTX-MC138 in metastatic | Jun 3, 2026 |
| SMMT | 8-K | neutral | 3/10 | Summit Therapeutics disclosed that its Audit Committee and independent directors approved company affiliates to purchase | Jun 3, 2026 |
| CORT | 8-K | bullish | 6/10 | Corcept disclosed that the DOJ, California Department of Insurance, and named Plaintiff States have all declined to inte | Jun 3, 2026 |
| NAMSW | 8-K | neutral | 3/10 | NewAmsterdam Pharma filed an 8-K reporting the results of its 2026 annual general meeting, where shareholders approved t | Jun 3, 2026 |
| ATAI | 8-K | neutral | 2/10 | AtaiBeckley filed an 8-K announcing management's participation in four investor conferences in June 2026, including the | Jun 3, 2026 |
| DYN | 8-K | bullish | 6/10 | Dyne Therapeutics announced full enrollment (71 participants) of the registrational expansion cohort in its Phase 1/2 AC | Jun 3, 2026 |
| TGTX | 8-K | bullish | 7/10 | TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI (ublituximab-xiiy), showing fa | Jun 3, 2026 |
| TGTX | PRESS-RELEASE | bullish | 7/10 | TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI, showing favorable pharmacokin | Jun 3, 2026 |
| DYN | PRESS-RELEASE | neutral | 5/10 | Dyne Therapeutics announced completion of enrollment in the registrational expansion cohort of the Phase 1/2 ACHIEVE tri | Jun 3, 2026 |
| RGNX | 8-K | neutral | 3/10 | REGENXBIO reported results of its 2026 Annual Meeting held May 29, 2026, where shareholders elected three Class II direc | Jun 3, 2026 |
| ARGX | 6-K | bullish | 5/10 | Argenx presented new long-term data for efgartigimod in myositis (ALKIVIA+ open-label extension) and Sjogren's disease ( | Jun 3, 2026 |
| OVID | 8-K | neutral | 2/10 | Ovid Therapeutics appointed Dr. Anna Greka, a Harvard Medical School professor and Broad Institute executive, as a Class | Jun 3, 2026 |
| COCP | 8-K | neutral | 4/10 | Cocrystal Pharma appointed James Sapirstein as CEO, effective immediately, replacing co-CEOs Sam Lee and Jim Martin. Lee | Jun 3, 2026 |
| KURA | PRESS-RELEASE | bullish | 7/10 | Kura Oncology presented Phase 1a data at ASCO 2026 showing darlifarnib + adagrasib achieved confirmed objective response | Jun 3, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed a Form 6-K on June 3, 2026, disclosing that management will participate in two investor conferences: a | Jun 3, 2026 |
| CATX | PRESS-RELEASE | neutral | 5/10 | Perspective Therapeutics announced the first patient dosed with [212Pb]VMT-α-NET in a new meningioma cohort of its ongoi | Jun 3, 2026 |
| TTRX | 8-K | bullish | 7/10 | Turn Therapeutics released an updated investor presentation at the Jefferies Global Healthcare Conference, disclosing po | Jun 3, 2026 |
| DRUG | 6-K | neutral | 2/10 | Bright Minds Biosciences filed its management information circular for the March 31, 2026 annual general meeting. The ci | Jun 3, 2026 |
| PRNAF | 6-K | neutral | 1/10 | Alterity Therapeutics filed a Form 6-K on June 3, 2026, solely to report a change in its registered office address to Le | Jun 3, 2026 |
| IDYA | 8-K | neutral | 4/10 | IDEAYA announced a clinical collaboration with Roche to evaluate its PRMT5 inhibitor IDE892 in combination with Roche's | Jun 3, 2026 |
| BCLI | EFFECT | bearish | 5/10 | BrainStorm Cell Therapeutics' S-1 registration statement (File No. 333-296090) was declared effective by the SEC on June | Jun 3, 2026 |